China Market Intelligence

August 7th, 2019
By USCBC Staff

On July 31, US-China Business Council (USCBC) President Craig Allen testified before the US-China Economic Security Review Commission (USCC) on US companies’ access, risks, and opportunities in China’s health market. His testimony was part of a full day of hearings titled “Exploring the Growing US Reliance on China’s Biotech and Pharmaceutical Products.”

USCC was created to monitor and investigate the national security implications of the bilateral trade and economic relationship, and...

February 27th, 2019
By USCBC Staff
The 13th National People’s Congress (NPC) kicks-off in Beijing on March 5. Convening just after trade negotiations were extended, it will be important to watch how China’s government deals with key issues such as the Foreign Investment Law, which is expected to pass. USCBC will be monitoring outcomes daily to provide members timely information on major developments.

The 13th National People’s Congress (NPC), China’s top legislature, will begin in Beijing on March 5 and last around...

January 16th, 2019
By Chynna Hawes

Draft amendments make some progress in strengthening China’s intellectual property rights (IPR) system, including by increasing penalties, extending patent term for designs, and adding patent term restoration for innovative pharmaceuticals.

Remaining concerns include vague language, enforceability, and lack of a patent linkage system, a key issue for US pharmaceuticals.  

This is an important opportunity to advocate the interests of US...

September 20th, 2018
By Chynna Hawes

On September 7, the 13th National People’s Congress Standing Committee (NPCSC), China’s constitutional authority, released its five-year legislative plan, outlining and prioritizing major legislative tasks into three classes that, in principle, are listed in descending priority; however, items are not passed or deliberated in sequence.

The 13th NPCSC's legislative plan includes 69 “Class I” projects to be completed by March 2023. However, many Class I projects...

September 20th, 2018
By Chynna Hawes

China’s regulators recently released the first drug traceability proposal since China suspended its previous system in 2016 because of a number of challenges, including complaints of unfair competition and that the government-issued serial number was not compliant with GS1 global standards for pharmaceutical traceability. The goal of the new proposal is to establish a system to trace drugs through the supply chain, prevent counterfeit and substandard drugs from entering the supply...

August 8th, 2018
By Chynna Hawes

The Shanghai Free Trade Zone (FTZ) Market Regulatory Authority (MRA) recently issued a penalty decision against a foreign medical product distributor for false promotion under the Anti-unfair Competition Law (AUCL), the revised version of which came into effect January 1. The recently created State Authority for Market Regulation (SAMR) assumed enforcement responsibilities for the AUCL, and in May announced it would step up implementation with a six-month campaign through October....

July 11th, 2018
By Ricky Altieri

China has implemented new rules setting requirements on the storage, use, and flow of scientific data. Although intended to strengthen data security and promote data sharing, the measures could affect companies’ university partnerships and R&D centers in the pharmaceutical, automotive and tech industries.

The Administrative Measures for Scientific Data Management were released by the Ministry of Science and Technology (MOST) in April, and immediately put into...

June 27th, 2018
By Anna Ashton

US companies now have stronger recourse against Chinese businesses that claim Chinese law as a protection for unfair practices. According to a unanimous US Supreme Court ruling earlier this month, Chinese government claims about what its law requires do not automatically protect Chinese companies that violate US law.  

US vitamin C purchasers Animal Science Products Inc and Ranis Co. accused Chinese vitamin C producers of violating US antitrust laws by colluding to...

February 7th, 2018
By David Solomon

China’s National Development and Reform Commission (NDRC) recently announced its 2018 priorities for pricing investigations under the anti-monopoly law (AML), listing key industries in which it says price-fixing tactics impact the day-to-day lives of Chinese citizens.

According to a CCTV report, NDRC will intensify enforcement in bulk pharmaceutical chemicals, scarce drugs, medical devices, automotive equipment, natural gas, tap water, electricity, industrial raw...

November 8th, 2017
By David Solomon

Chinese regulations on tendering and bidding practices published by the Ministry of Finance (MOF) in July are a promising sign for US pharmaceutical and medical device manufacturers that government procurement behavior will be better regulated to guarantee consideration of quality alongside price. However, true improvement for the industry will require regulators to faithfully implement the law and refrain from unofficial practices such as local favoritism, which sometimes plague...

Pages